U.S. government allows few suppliers to resume sales to Huawei
By Nikita Chaurasia  Date: 2019-11-21

U.S. government allows few suppliers to resume sales to Huawei
  • There had been no announcements about which product has been given an approval
  • Only narrow licenses are being issued to authorize limited and specific activities

The U.S. administration granted a second lifeline to Huawei recently as it allowed certain suppliers to resume sales to the Chinese telecom giant. The sales would restart six months after it was blacklisted for trade over concerns for national security.

The U.S. Commerce Department stated that it has started granting licenses to certain companies so that they are able to sell goods to Huawei and expand the supplier base of the company. This will offer clarity to the industry that had been selling goods worth billions of dollars to the company.

Apparently, it is unclear as to which products have been given an approval to be sold to the top telecommunications equipment maker in the world. Huawei Technologies is the second largest maker of smartphones worldwide. The company has been waiting to procure a license that could help Google to supply the company’s mobile services to new models.

According to reliable sources, there have been requests for nearly 300 licenses out of which only half have been processed yet. Approximately half or one-quarter of the overall processed licenses have been given approval and the remaining have been denied. Some of the licenses for sale of both the cell phone components as well as non-electronic components have been approved.

The Commerce Department commented that it has been issuing narrow licenses to authorize only specific and limited activities that do not pose a major risk to the foreign policy interests or the national security of the United States.

Marco Rubio, Republican Senator, commented that Huawei poses a growing and clear threat to both the national and the economic security of the United States as well as its allies. Rubio said that he strongly believes that granting licenses for the U.S. exports that could strengthen and sustain Huawei is against the national security of America.

 

Source credit- https://www.reuters.com/article/us-usa-china-huawei-tech/some-huawei-suppliers-get-us-approval-to-restart-sales-to-blacklisted-firm-idUSKBN1XU21Q

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...